Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INTERCEPT PHARMACEUTICALS, INC.ICPT · Entity 108343 | Chief Qual. Officer & SVP Ops. | July 11, 2022 | July 13, 2022 |
| Whitehawk Therapeutics, Inc.WHWK · Entity 6074 | See remarks | September 15, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INTERCEPT PHARMACEUTICALS, INC.
Report date July 11, 2022 · Filed July 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,178 |
Reported balance
After 2022-07-11 transaction · row 1
1 source rowRow 1 · 2022-07-11 · Tax withholding · Disposed 436 · Balance 25,178 F1: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person.
Whitehawk Therapeutics, Inc.
Report date September 15, 2026 · Filed September 18, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.09 · Expires 2036-09-15 | Direct | 91,633 |
Reported balance
After 2026-09-15 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-09-15 · Grant · Acquired 91,633 · Balance 91,633 F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 91,633 |
Reported balance
After 2026-09-15 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2026-09-15 · Grant · Acquired 91,633 · Balance 91,633 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock. F3: The original Form 4 filed by the Reporting Person erroneously reflected an incorrect vesting schedule. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.
F3: The original Form 4 filed by the Reporting Person erroneously reflected an incorrect vesting schedule. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
IMMUNOMEDICS INC
Report date October 23, 2020 · Filed October 23, 2020
Section 16 reporting ended · disclosed 2020-10-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-23 transaction · row 1
1 source rowRow 1 · 2020-10-23 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.01 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was automatically cancelled and converted into the right to receive $88.00 in cash (the "Offer Price"), without interest and subject to required withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-10-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-10-23 · Disposition to issuer · Disposed 261,937 · Balance 0 F2: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.01 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was automatically cancelled and converted into the right to receive $88.00 in cash (the "Offer Price"), without interest and subject to required withholding taxes.
F2: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 18, 2026 20:44 UTC Amendment | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | GrantRestricted Stock Units · Derivative | 91,633 | $0.00 | $0.00 |
DisclosureSEC source: 0001766522-26-000017 · form4a-09182026_080958.xml · derivative · entry 2 BALL BRYAN · CIK 0001766522 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,633 Underlying: Common Stock · 91,633 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock. F3 · derivative.exercise_date: The original Form 4 filed by the Reporting Person erroneously reflected an incorrect vesting schedule. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026. F3 · derivative.expiration_date: The original Form 4 filed by the Reporting Person erroneously reflected an incorrect vesting schedule. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026. Read SEC document |
| September 15, 2026 Filed Sep 18, 2026 20:44 UTC Amendment | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | GrantStock Option (right to buy) · Derivative | 91,633 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0001766522-26-000017 · form4a-09182026_080958.xml · derivative · entry 1 BALL BRYAN · CIK 0001766522 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,633 Underlying: Common Stock · 91,633 shares Expires 2036-09-15 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026. Read SEC document |
| September 15, 2026 Filed Sep 15, 2026 23:05 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | GrantRestricted Stock Units · Derivative | 91,633 | $0.00 | $0.00 |
DisclosureSEC source: 0001766522-26-000015 · form4-09152026_110959.xml · derivative · entry 2 BALL BRYAN · CIK 0001766522 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,633 Underlying: Common Stock · 91,633 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest on each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean September 15, 2026. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest on each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean September 15, 2026. Read SEC document |
| September 15, 2026 Filed Sep 15, 2026 23:05 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | GrantStock Option (right to buy) · Derivative | 91,633 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0001766522-26-000015 · form4-09152026_110959.xml · derivative · entry 1 BALL BRYAN · CIK 0001766522 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,633 Underlying: Common Stock · 91,633 shares Expires 2036-09-15 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:05 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | GrantCommon Stock | 51,020 | $3.92 | $199,998.40 |
DisclosureSEC source: 0001766522-26-000013 · form4-05182026_080529.xml · nonDerivative · entry 1 BALL BRYAN · CIK 0001766522 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 448,126 Read SEC document |
| April 14, 2026 Filed Apr 15, 2026 23:59 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | SaleCommon Stock | 92,460 | $3.64 | $336,554.40 |
DisclosureSEC source: 0001766522-26-000011 · form4-04152026_110455.xml · nonDerivative · entry 2 BALL BRYAN · CIK 0001766522 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 397,106 F1 · kind: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| April 13, 2026 Filed Apr 15, 2026 23:59 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | SaleCommon Stock | 26,389 | $3.46 | $91,305.94 |
DisclosureSEC source: 0001766522-26-000011 · form4-04152026_110455.xml · nonDerivative · entry 1 BALL BRYAN · CIK 0001766522 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 489,566 F1 · kind: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| April 10, 2026 Filed Apr 14, 2026 00:34 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | SaleCommon Stock | 6,596 | $3.43 | $22,624.28 |
DisclosureSEC source: 0001766522-26-000009 · form4-04142026_120420.xml · nonDerivative · entry 2 BALL BRYAN · CIK 0001766522 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 515,955 F1 · kind: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| April 09, 2026 Filed Apr 14, 2026 00:34 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | SaleCommon Stock | 50,000 | $3.57 | $178,500.00 |
DisclosureSEC source: 0001766522-26-000009 · form4-04142026_120420.xml · nonDerivative · entry 1 BALL BRYAN · CIK 0001766522 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 522,551 F1 · kind: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 22:20 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | GrantStock Option (right to buy) · Derivative | 250,058 | $0.00 Strike: $3.54 | $0.00 |
DisclosureSEC source: 0001766522-26-000005 · form4-04032026_100426.xml · derivative · entry 3 BALL BRYAN · CIK 0001766522 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,058 Underlying: Common Stock · 250,058 shares Expires 2036-04-01 F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the Option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2026. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 22:20 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | Exercise / conversionRestricted Stock Units · Derivative | 366,532 | $0.00 | $0.00 |
DisclosureSEC source: 0001766522-26-000005 · form4-04032026_100426.xml · derivative · entry 2 BALL BRYAN · CIK 0001766522 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 366,532 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock. F2 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2025. F2 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2025. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 22:20 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | Exercise / conversionCommon Stock | 366,532 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001766522-26-000005 · form4-04032026_100426.xml · nonDerivative · entry 1 BALL BRYAN · CIK 0001766522 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 572,551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock. Read SEC document |
| March 02, 2026 Filed Mar 10, 2026 23:35 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | SaleCommon Stock | 1,834 | $3.31 | $6,069.81 |
DisclosureSEC source: 0001766522-26-000002 · form4-03102026_110307.xml · nonDerivative · entry 2 BALL BRYAN · CIK 0001766522 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,019 F2 · kind: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 01, 2026 Filed Mar 10, 2026 23:35 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001766522-26-000002 · form4-03102026_110307.xml · derivative · entry 3 BALL BRYAN · CIK 0001766522 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean March 1, 2024. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean March 1, 2024. Read SEC document |
| March 01, 2026 Filed Mar 10, 2026 23:35 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | Exercise / conversionCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001766522-26-000002 · form4-03102026_110307.xml · nonDerivative · entry 1 BALL BRYAN · CIK 0001766522 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 207,853 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 23:24 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | GrantRestricted Stock Units · Derivative | 366,532 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010080 · form4-04032025_110433.xml · derivative · entry 2 BALL BRYAN · CIK 0001766522 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 366,532 Underlying: Common Stock · 366,532 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2025. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2025. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 23:24 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | GrantStock Option (right to buy) · Derivative | 366,532 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001415889-25-010080 · form4-04032025_110433.xml · derivative · entry 1 BALL BRYAN · CIK 0001766522 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 366,532 Underlying: Common Stock · 366,532 shares Expires 2035-04-01 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the Option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2025. Read SEC document |
| March 04, 2025 Filed Mar 4, 2025 23:09 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | GrantCommon Stock | 100,000 | $2.40 | $240,000.00 |
DisclosureSEC source: 0001415889-25-006676 · form4-03042025_110346.xml · nonDerivative · entry 3 BALL BRYAN · CIK 0001766522 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,853 Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 23:09 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 2,147 | $2.35 | $5,045.45 |
DisclosureSEC source: 0001415889-25-006676 · form4-03042025_110346.xml · nonDerivative · entry 2 BALL BRYAN · CIK 0001766522 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,853 F2 · kind: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 23:09 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006676 · form4-03042025_110346.xml · derivative · entry 4 BALL BRYAN · CIK 0001766522 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Aadi Bioscience, Inc. Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean March 1, 2024. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean March 1, 2024. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 23:09 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | Exercise / conversionCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-006676 · form4-03042025_110346.xml · nonDerivative · entry 1 BALL BRYAN · CIK 0001766522 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Aadi Bioscience, Inc. Common Stock. Read SEC document |
| July 11, 2022 Filed Jul 13, 2022 16:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 436 | $14.57 | $6,352.52 |
DisclosureSEC source: 0001104659-22-079500 · tm2220932d1_4.xml · nonDerivative · entry 1 BALL BRYAN · CIK 0001766522 · Chief Qual. Officer & SVP Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,178 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person. Read SEC document |
| April 11, 2022 Filed Apr 13, 2022 16:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 531 | $17.19 | $9,127.89 |
DisclosureSEC source: 0001104659-22-045468 · tm2212611-1_4seq1.xml · nonDerivative · entry 1 BALL BRYAN · CIK 0001766522 · Chief Qual. Officer & SVP Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,614 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 16:13 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 6,100 | $0.00 Strike: $14.44 | $0.00 |
DisclosureSEC source: 0001104659-22-009549 · tm224882-1_4seq1.xml · derivative · entry 2 BALL BRYAN · CIK 0001766522 · Chief Qual. Officer & SVP Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,100 Underlying: Common Stock · 6,100 shares Expires 2032-01-27 F2 · derivative.exercise_date: The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2022. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 16:13 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 3,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-009549 · tm224882-1_4seq1.xml · nonDerivative · entry 1 BALL BRYAN · CIK 0001766522 · Chief Qual. Officer & SVP Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,145 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2022. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 19:04 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 2,455 | $16.83 | $41,317.65 |
DisclosureSEC source: 0001104659-22-004113 · tm222949-1_4seq1.xml · nonDerivative · entry 1 BALL BRYAN · CIK 0001766522 · Chief Qual. Officer & SVP Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,545 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person. Read SEC document |
| January 11, 2021 Filed Jan 11, 2021 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 39,185 | $0.00 Strike: $31.26 | $0.00 |
DisclosureSEC source: 0001104659-21-003101 · tm212854-2_4seq1.xml · derivative · entry 2 BALL BRYAN · CIK 0001766522 · Chief Quality Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,185 Underlying: Common Stock · 39,185 shares Expires 2031-01-11 F2 · derivative.exercise_date: The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 11, 2021. Read SEC document |
| January 11, 2021 Filed Jan 11, 2021 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-003101 · tm212854-2_4seq1.xml · nonDerivative · entry 1 BALL BRYAN · CIK 0001766522 · Chief Quality Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting in an initial annual installment following the Vesting Commencement Date and the remaining shares vesting pro rata on each subsequent three-month anniversary of the Vesting Commencement Date. The Vesting Commencement Date is January 11, 2021. Read SEC document |
| October 23, 2020 Filed Oct 23, 2020 17:33 UTC | IMMUNOMEDICS INC IMMU · Entity 145732 | Disposition to issuerStock Option (Right to Buy) · Derivative | 261,937 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-117796 · a4.xml · derivative · entry 2 BALL BRYAN · CIK 0001766522 · Chief Quality Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 261,937 shares Expires not disclosed F2 · derivative.exercise_price: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration. F2 · price: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration. F2 · derivative.expiration_date: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration. Read SEC document |
| October 23, 2020 Filed Oct 23, 2020 17:33 UTC | IMMUNOMEDICS INC IMMU · Entity 145732 | Disposition to issuerCommon Stock | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-117796 · a4.xml · nonDerivative · entry 1 BALL BRYAN · CIK 0001766522 · Chief Quality Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.01 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was automatically cancelled and converted into the right to receive $88.00 in cash (the "Offer Price"), without interest and subject to required withholding taxes. F1 · price: In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.01 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was automatically cancelled and converted into the right to receive $88.00 in cash (the "Offer Price"), without interest and subject to required withholding taxes. Read SEC document |
| March 04, 2020 Filed Mar 5, 2020 17:01 UTC | IMMUNOMEDICS INC IMMU · Entity 145732 | GrantStock Option (right to buy) · Derivative | 51,600 | $0.00 Strike: $17.16 | $0.00 |
DisclosureSEC source: 0001104659-20-029759 · a4.xml · derivative · entry 1 BALL BRYAN · CIK 0001766522 · Chief Quality Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,600 Underlying: Common Stock, par value $0.01 per share · 51,600 shares Expires 2027-03-04 F1 · derivative.exercise_date: The reporting person was granted stock options pursuant to the Issuer's 2014 Long-Term Incentive Plan (the "Plan"). The stock options vest 25% on the first anniversary of the date of grant, and on a quarterly basis thereafter over a three year period. Read SEC document |
| October 03, 2019 Filed Oct 3, 2019 17:30 UTC | IMMUNOMEDICS INC IMMU · Entity 145732 | PurchaseCommon Stock, $0.01 par value per share | 5,000 | $14.18 | $70,896.50 |
DisclosureSEC source: 0001104659-19-053001 · a4.xml · nonDerivative · entry 1 BALL BRYAN · CIK 0001766522 · Chief Quality Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| September 10, 2019 Filed Sep 10, 2019 18:00 UTC | IMMUNOMEDICS INC IMMU · Entity 145732 | GrantStock Option (right to buy) · Derivative | 10,440 | $0.00 Strike: $15.59 | $0.00 |
DisclosureSEC source: 0001104659-19-049586 · a4.xml · derivative · entry 2 BALL BRYAN · CIK 0001766522 · Chief Quality Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,440 Underlying: Common Stock, par value $0.01 per share · 10,440 shares Expires 2026-09-10 F1 · derivative.exercise_date: The reporting person was granted stock options pursuant to the Issuer's 2014 Long-Term Incentive Plan. The stock options vest 25% on the first anniversary of the date of grant, and in 6.25% in equal quarterly installments over a three-year period thereafter. Read SEC document |
| September 06, 2019 Filed Sep 10, 2019 18:00 UTC | IMMUNOMEDICS INC IMMU · Entity 145732 | GrantStock Option (right to buy) · Derivative | 57,040 | $0.00 Strike: $13.19 | $0.00 |
DisclosureSEC source: 0001104659-19-049586 · a4.xml · derivative · entry 1 BALL BRYAN · CIK 0001766522 · Chief Quality Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,040 Underlying: Common Stock, par value $0.01 per share · 57,040 shares Expires 2026-09-06 F1 · derivative.exercise_date: The reporting person was granted stock options pursuant to the Issuer's 2014 Long-Term Incentive Plan. The stock options vest 25% on the first anniversary of the date of grant, and in 6.25% in equal quarterly installments over a three-year period thereafter. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 08:47 UTC | IMMUNOMEDICS INC IMMU · Entity 145732 | PurchaseCommon Stock, $0.01 par value per share | 5,000 | $13.35 | $66,750.00 |
DisclosureSEC source: 0001104659-19-036862 · a4.xml · nonDerivative · entry 1 BALL BRYAN · CIK 0001766522 · Chief Quality Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 18:39 UTC | IMMUNOMEDICS INC IMMU · Entity 145732 | GrantStock Option (right to buy) · Derivative | 142,857 | $0.00 Strike: $16.96 | $0.00 |
DisclosureSEC source: 0001104659-19-013436 · a4.xml · derivative · entry 1 BALL BRYAN · CIK 0001766522 · Chief Quality Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,857 Underlying: Common Stock, par value $0.01 per share · 142,857 shares Expires 2026-03-05 F1 · derivative.exercise_date: The reporting person was granted stock options pursuant to the Company's 2014 Long-Term Incentive Plan. The stock options vest 25% on the first anniversary of the date of grant and 6.025% on a quarterly basis thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.